Furthermore, since GM-CSF-induced DCs are a key player in inflammation and autoimmunity (17), Mst1 can be a new and considerable therapeutic target in the treatment of GM-CSF-derived inflammatory diseases, such as multiple sclerosis, rheumatoid arthritis, and inflammatory bowel disease (17, 53). This evidence concerns the gene CSF2 and multiple sclerosis.